SCHEMBL1552743

SCHEMBL1552743

O=C(c1ccccc1)c1ccc2c(c1)C1(c3ccccc3-c3ccccc31)c1ccccc1-2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 5/20 0.66
TDP1 Q9NUW8 2/20 0.52
ATM Q13315 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 1/20 0.48
SRD5A2 P31213 1/20 0.47
PTPRC P08575 1/20 0.46
CYP2C8 P10632 1/20 0.46
CYP2C9 P11712 1/20 0.46
MEN1 O00255 2/20 0.45
RAB9A P51151 2/20 0.45
KMT2A Q03164 2/20 0.45
NPC1 O15118 1/20 0.45
PBRM1 Q86U86 1/20 0.44
CNR2 P34972 1/20 0.44
THRB P10828 1/20 0.43
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
MAPK13 O15264 1/20 0.42
MAPK12 P53778 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL133477 1.00 PDK2 (0.66) PDK2TDP1ATML3MBTL1ALDH1A1
SCHEMBL12337045 0.96 PDK2 (0.60) PDK2TDP1ATML3MBTL1ALDH1A1
SCHEMBL134286 0.95 PDK2 (0.58) PDK2TDP1ATML3MBTL1THRB
SCHEMBL134285 0.95 PDK2 (0.58) PDK2TDP1ATML3MBTL1THRB
SCHEMBL29114 0.95 PDK2 (0.58) PDK2TDP1ATML3MBTL1THRB
SCHEMBL13702055 0.93 PDK2 (0.57) PDK2TDP1ATML3MBTL1PTPRC
SCHEMBL13702054 0.91 PDK2 (0.55) PDK2TDP1ATML3MBTL1THRB
SCHEMBL18567976 0.91 PDK2 (0.57) PDK2TDP1ATML3MBTL1ALDH1A1
SCHEMBL17928299 0.91 PDK2 (0.57) PDK2TDP1ATML3MBTL1ALDH1A1
SCHEMBL12200611 0.90 PDK2 (0.54) PDK2TDP1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228523-A1 Metal complexes UDC IRELAND LTD (IE) 2024-07-11 US disclosed
US-9634256-B2 Electroluminescent devices including organic EIL layer GLOBAL OLED TECHNOLOGY LLC (US) 2017-04-25 US disclosed
US-9634256-B2 Electroluminescent devices including organic EIL layer GLOBAL OLED TECHNOLOGY LLC (US) 2017-04-25 US disclosed
US-20150311447-A1 ELECTROLUMINESCENT DEVICES INCLUDING ORGANIC EIL LAYER GLOBAL OLED TECHNOLOGY LLC (US) 2015-10-29 US disclosed
US-9118020-B2 Electroluminescent devices including organic eil layer GLOBAL OLED TECHNOLOGY LLC (US) 2015-08-25 US disclosed
US-8188462-B2 Spirobifluorene derivatives, their preparation and uses thereof MERCK PATENT GMBH (DE) 2012-05-29 US disclosed
EP-1534661-B1 SPIROBIFLUORENE DERIVATIVES, THEIR PREPARATION AND USES THEREOF MERCK PATENT GMBH (DE) 2011-04-27 EP disclosed
US-20100084647-A1 ELECTROLUMINESCENT DEVICES INCLUDING ORGANIC EIL LAYER GLOBAL OLED TECHNOLOGY LLC 2010-04-08 US disclosed
US-20090302274-A1 SPIROBIFLUORENE DERIVATIVES, THEIR PREPARATION AND USES THEREOF MERCK PATENT GMBH (DE) 2009-12-10 US disclosed
US-7557249-B2 Spirobifluorene derivatives, their preparation and uses thereof MERCK PATENT GMBH (DE) 2009-07-07 US disclosed
US-20070252516-A1 Electroluminescent devices including organic EIL layer EASTMAN KODAK COMPANY 2007-11-01 US disclosed
US-20060006365-A1 Spirobifluorene derivatives, their preparation and uses thereof COVION ORGANIC SEMICONDUCTORS GMBH (DE) 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228523-A1 Metal complexes MCU, IMMT, SOD1 PDK2 2377/4885TDP1 2252/4885ATM 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.